VCM
VNDA icon

Versant Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Versant Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8K Buy
2,417
+55
+2% +$359 ﹤0.01% 2081
2026
Q1 		$16.3K Hold
2,362
– – ﹤0.01% 1915
2025
Q4 		$20.8K Buy
+2,362
New +$13K ﹤0.01% 1613
2025
Q2 		– Sell
-87
Closed -$399 – 2736
2025
Q1 		$399 Sell
87
-484
-85% -$2.26K ﹤0.01% 2427
2024
Q4 		$2.73K Buy
571
+547
+2,279% +$2.63K ﹤0.01% 1982
2024
Q3 		$113 Hold
24
– – ﹤0.01% 1982
2024
Q2 		$136 Hold
24
– – ﹤0.01% 1922
2024
Q1 		$99 Sell
24
-238
-91% -$953 ﹤0.01% 1862
2023
Q4 		$1.11K Buy
262
+22
+9% +$89 ﹤0.01% 1483
2023
Q3 		$1.04K Buy
240
+66
+38% +$367 ﹤0.01% 1515
2023
Q2 		$1.15K Hold
174
– – ﹤0.01% 1552
2023
Q1 		$1.17K Sell
174
-661
-79% -$4.65K ﹤0.01% 1405
2022
Q4 		$6.17K Sell
835
-27
-3% -$263 ﹤0.01% 812
2022
Q3 		$9K Buy
862
+5
+0.6% +$53 ﹤0.01% 690
2022
Q2 		$9K Buy
857
+109
+15% +$1.13K ﹤0.01% 702
2022
Q1 		$8K Sell
748
-37
-5% -$486 ﹤0.01% 760
2021
Q4 		$12K Buy
785
+34
+5% +$592 ﹤0.01% 672
2021
Q3 		$13K Sell
751
-91
-11% -$1.59K ﹤0.01% 628
2021
Q2 		$18K Sell
842
-366
-30% -$6.55K 0.01% 523
2021
Q1 		$18K Buy
1,208
+147
+14% +$2.38K 0.01% 596
2020
Q4 		$13K Buy
1,061
+7
+0.7% +$84 0.01% 660
2020
Q3 		$10K Buy
1,054
+270
+34% +$2.89K ﹤0.01% 669
2020
Q2 		$8K Sell
784
-122
-13% -$1.38K ﹤0.01% 712
2020
Q1 		$9K Buy
+906
New +$11.2K ﹤0.01% 595

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's VNDA Position: Q2 2026 in Review

Versant Capital Management increased its Vanda Pharmaceuticals (VNDA) stake by 2.3% in Q2 2026, buying an estimated $359 and bringing the position to 2,417 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Versant Capital Management first reported a position in VNDA in Q1 2020 and has held it in 24 quarters since. The position peaked at $20.8K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Versant Capital Management held 2,417 shares of Vanda Pharmaceuticals worth $14.8K as of Q2 2026.
  • Versant Capital Management bought 55 Vanda Pharmaceuticals shares in Q2 2026, an estimated $359.
  • Vanda Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2081 holding.
  • Versant Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2020 and has held it in 24 quarters since.
  • Versant Capital Management's Vanda Pharmaceuticals position peaked at $20.8K in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.